New cases of<unk>  in 2016. Disability-adjusted life year for<unk>  per 100,000 inhabitants in 2004 In 2018, there were 208,619 new cases of<unk>  recorded, a slight decrease from 2017. In 2015, 94% of the new<unk>  cases were confined to 14 countries. India reported the greatest number of new cases (60% of reported cases), followed by Brazil (13%) and Indonesia (8%). Although the number of cases worldwide continues to fall, there are parts of the world where<unk>  is more common, including Brazil, South Asia (India, Nepal, Bhutan), some parts of Africa (Tanzania, Madagascar, Mozambique), and the western Pacific. About 150 to 250 cases are diagnosed in the United States each year. In the 1960s, there were tens of millions of<unk>  cases recorded when the bacteria started to develop resistance to dapsone, the most common treatment option at the time. International (e.g., the WHO's "Global Strategy for Reducing Disease Burden Due to<unk> ") and national (e.g., the International Federation of Anti-Leprosy Associations) initiatives have reduced the total number and the number of new cases of the disease. Disease burden The number of new<unk>  cases is difficult to measure and monitor because of<unk> 's long incubation period, delays in diagnosis after onset of the disease, and lack of medical care in affected areas. The registered prevalence of the disease is used to determine disease burden. Registered prevalence is a useful proxy indicator of the disease burden, as it reflects the number of active<unk>  cases diagnosed with the disease and receiving treatment with MDT at a given point in time. The prevalence rate is defined as the number of cases registered for MDT treatment among the population in which the cases have occurred, again at a given point in time.
Leprosy
Sporotrichosis
Onychomycosis
Mumps
Tinea barbae
Tinea faciei
Trichinosis
Tinea manuum